<DOC>
	<DOCNO>NCT03089697</DOCNO>
	<brief_summary>This study perform evaluate safety explore efficacy single intravenous dose N-Rephasin® SAL200 ( 3 mg/kg ) addition conventional standard treatment , persistent Staphylococcus aureus bacteremia patient , 48 hour even antibiotic treatment Staphylococcus aureus susceptible .</brief_summary>
	<brief_title>Phase IIa Clinical Study N-Rephasin® SAL200</brief_title>
	<detailed_description>Subjects : Patients persistent Staphylococcus aureus bacteremia 48 hour begin antibiotic treatment Staphylococcus aureus susceptible . Study Method : 1 . Selection patient persistent S.aureus bacteremia 48 hour even application standard treatment S. aureus bacteremia 2 . Randomization accord trial institution 3 . The control group receive single intravenous dose placebo addition standard treatment persistent Staphylococcus aureus bacteremia 4 . The study group receive single intravenous dose N-Rephasin® SAL200 ( 3 mg/kg ) addition standard treatment persistent Staphylococcus aureus bacteremia 5 . A blood culture perform 18 hour ( ±6 hour ) administration N-Rephasin® SAL200 6 . Blood culture continue perform every 24 hour ( ±6 hour ) 48 hour ( ±6 hour ) previous blood culture , two consecutive result 'no growth ( negative conversion ) ' obtain 7 . Adverse event monitor time first blood culture follow administration N-Rephasin® SAL200 placebo , subsequent interval 24 hour 48 hour Statistical Analysis : 1 . Primary endpoint - Safety analysis conduct Safety group . A distribution table patient experience least one adverse event ( incidence ) , distribution table relationship report adverse event investigational product ( distribution table severity relationship drug ) present respect group ( study group , control group ) , determine safety investigational product . - The result laboratory test , anaphylaxis test , inflammatory cytokine test vital sign baseline last visit summarize mean value standard deviation , determine change treatment within group . - Categorical data divide normal abnormal , summarized frequency percentage determine difference treatment within group . 2 . Secondary endpoint - Proportion patient negative bacterial growth first blood culture administration investigational drug . The descriptive statistic proportion patient negative bacterial growth first blood culture ( rate growth ) first treatment presented treatment group . Whether rate growth superior study group compare control group , evaluate descriptive statistical method . - Proportion patient die due S. aureus bacteremia Day14 incidence bacteremia . The descriptive statistic proportion patient die due S. aureus bacteremia Day14 present treatment group evaluate . - Proportion treatment failure S. aureus bacteremia Day 14 ( two consecutive result 'no growth ' achieve blood culture perform Day 14 . The descriptive statistic proportion treatment failure S. aureus bacteremia Day 14 present evaluate .</detailed_description>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Methicillin</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>1 . Patients MSSA/MRSA bacteremia confirm pair Gram positive bacteria blood culture conduct 48~96 hour start antibiotic treatment S. aureus susceptible . 2 . Males female age 19 year old 3 . Those understand explanatory note subject , sign inform consent . 1 . Those receive appropriate antibiotic within 48 hour occurrence bacteremia ( time point reporting department laboratory medicine ) 2 . The Gram positive strain , identify blood culture conduct 48~96 hour start antibiotic treatment S. aureus susceptible , strain S. aureus culture definite diagnosis S. aureus bacteremia make 3 . Those pass 48 hour confirmation persistent S. aureus bacteremia blood culture conduct 48~96 hour start antibiotic treatment S. aureus susceptible 4 . Those symptom septic shock time acquisition consent form Systolic blood pressure low 90 mmHg , blood pressure low usual 40 mmHg , spite application appropriate fluid therapy Requirement hypertensor maintain systolic blood pressure 90 mmHg high 5 . Those infected mixed bacterial specie 6 . Those hypersensitive NRephasin® SAL200 , clinically significant hypersensitivity , past history 7 . Pregnant lactate woman woman childbearing potential ( agree take appropriate contraceptive measure trial period ) 8 . Those participated clinical trial within 30 day prior enrollment 9 . Patients condition may interfere study participation accurate evaluation investigator 's judgment 10 . Those may die within 72 hour due serious complication ( e.g. , cerebral infarction , etc . ) , per investigator 's judgment</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>N-Rephasin SAL200</keyword>
	<keyword>Methicillin-Sensitive Staphylococcus aureus</keyword>
	<keyword>Methicillin Resistant Staphylococcus Aureus</keyword>
</DOC>